Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours (Q40592751)
Jump to navigation
Jump to search
scientific article published on May 1, 2003
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours |
scientific article published on May 1, 2003 |
Statements
1 reference
Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours (English)
1 reference
Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours (English)
1 reference
1 reference
Eskens FA
1 reference
F. A L M. Eskens
H. Dumez
R. Hoekstra
A. Perschl
C. Brindley
S. Böttcher
W. Wynendaele
J. Drevs
J. Verweij
A. T. van Oosterom
1 May 2003
1 reference
1 reference
1 reference
Identifiers
1 reference